SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense community debate following an earnings beat that included raised guidance and strong US commercial growth, with bulls viewing the current stagnant price action as a manipulation-driven buying opportunity while bears emphasize concerns over valuation and the reliance on government contracts.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARB IOT Group is capturing significant attention as a low-float momentum play, with community members actively discussing its potential for a major short squeeze driven by a tight share supply and recent high volume. Traders are closely watching key technical resistance levels, fueled by speculation surrounding contract wins and ambitious expectations for a parabolic move similar to other recent market runners.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies (XNDU) is experiencing extreme volatility as traders weigh a major structural shift in share supply from a resale registration filing against the company's long-term potential in photonic quantum computing. While some investors fear immediate dilution and exit pressure, others are closely watching high borrow fees and the possibility of a short squeeze, leading to intense community debate over whether this represents a fundamental reset or a temporary overreaction.

SKK Holdings Ltd. operates as a holding company, which engages in the provision of civil engineering services in subsurface utility works, including power and telecommunication cable laying, water pipeline and sewer rehabilitation works. The company was founded by Chun Seong Ng and Koon Kiat Sze on October 16, 2013 and is headquartered in Singapore.

SKK Holdings Ltd. - Ordinary Shares - Class A

SKK Holdings Ltd

SKK Holdings is trending due to a significant drone asset acquisition agreement that has triggered extreme volatility and a massive surge in volume. The community is sharply divided, with bulls aggressively chasing the micro-float momentum and speculative price targets, while bears are warning of potential long-term dilution and characterizing the stock as a volatile pump-and-dump candidate.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is facing intense market skepticism as investors debate whether generative AI poses a structural threat to its language-learning model or if the current sell-off represents an oversold buying opportunity. While bulls point to strong user engagement metrics and the company's long-term habit-retention moat, bears argue that decelerating growth and aggressive competition from free AI tools signal a permanent shift in the company's outlook.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest shares are surging following a significant $1 billion investment from Elliott Investment Management and the announcement of a massive $3.5 billion share repurchase program. The community is actively debating the stock's valuation, with many investors viewing the buyback as a major catalyst for a long-term turnaround while others remain focused on the company's competitive position and potential acquisition interest.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending following the CLARITY Act's progress and broader crypto sector gains, though community discussion remains split between strong bullish sentiment regarding its stablecoin infrastructure and concerns over legislative volatility. Investors are closely tracking technical levels and potential institutional adoption as the stock demonstrates sharp price expansion and heavy option volume.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals is seeing intense volatility and massive volume following an oversubscribed private placement financing, sparking heavy retail interest. The community is actively debating the stock's potential for further squeeze-driven gains versus the risks of dilution, with many focusing on its low float and ongoing technical battles between bulls and short sellers.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

Mask Network is trending following a significant capital infusion through a convertible note deal, which investors are viewing as a major catalyst to accelerate the company's Nordic AI infrastructure and data center projects. Community discussions are heavily focused on the stock's high volatility and after-hours volume, with many traders drawing parallels to other low-float momentum plays currently moving in the market.

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

GeneDx Holdings Corp - Ordinary Shares - Class A

GeneDx Holdings Corp

GeneDx Holdings is experiencing significant volatility following a guidance reset and weaker-than-expected earnings, leading to intense debate among investors regarding whether the stock is an oversold buying opportunity or a deeper valuation trap. Community sentiment is starkly divided, with many traders focusing on the recent sharp decline and potential for a technical bounce, while others highlight the company's long-term growth prospects and recent insider buying as evidence that the selloff may be overdone.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

#MarketMyopia #COVID19  $BNTX $PFE $MRNA  The &quot;less than fully intelligent&quot; analysts and investors are apparently not aware that the proof that mRNA works in vivo is one of the biggest accomplishments in medicine we&#39;ve seen in the past two centuries. It will be applied in many different treatment protocols going forward. They pretend also that vaccination is not required now because nobody dies, but they forget the huge cost for the 50% who were still hospitalized in the Merck study (posted/bought Merck 2 days ago btw).  Insurers (and patients whose bodies may still be damaged by COVID) hate hospitalizations for good reason. Still need the vaccines as much as we did before, and the market has also buried one of the leads at BNTX today as they begin a Phase 2 study of personalized colon cancer vaccines.  Market Myopia as usual.

Manu B

blanketyblank

Adam

#RespondRatherThanReact  The best entry opportunities in #markets come when #investors react in a reflexive and emotional manner, because they lack understanding.  Respond to their reaction by action or inaction as appropriate.  Do you really want to react and sell?  It&#39;s your choice.  React or respond?   As I say repeatedly, &quot;Respond rather than react.&quot;

StockTwits Web

David Durand

Moderna Inc

Pfizer Inc

BioNTech SE - ADR

  The "less than fully intelligent" analysts and investors are apparently not aware that the proof that mRNA works in vivo is one of the biggest accomplishments in medicine we've seen in the past two centuries. It will be applied in many different treatment protocols going forward. They pretend also that vaccination is not required now because nobody dies, but they forget the huge cost for the 50% who were still hospitalized in the Merck study (posted/bought Merck 2 days ago btw).  Insurers (and patients whose bodies may still be damaged by COVID) hate hospitalizations for good reason. Still need the vaccines as much as we did before, and the market has also buried one of the leads at BNTX today as they begin a Phase 2 study of personalized colon cancer vaccines.  Market Myopia as usual.

@SunAndStorm I think children not covered in Merck trial? I would not take risk with my child but get a vaccine for the kid as soon as it is approved. Long term, these are great opportunity to buy more $BNTX and others.

Guenther Unger

 I think children not covered in Merck trial? I would not take risk with my child but get a vaccine for the kid as soon as it is approved. Long term, these are great opportunity to buy more 

Ashu

#COVID19 #MerckCOVIDDrug  @new2investing01 Kids always get approved later due to the potential impact on development.  Kids get exposed to one protein from the vaccine and to all of them with the virus itself (same as adults).  Delta is going to find nearly everyone in the end, a process that is simply &quot;natural vaccination,&quot; which is a tougher way to go for many, including &quot;unlucky&quot; supposedly healthy younger patients.  But of course, discuss with the pediatrician as needed.  ;)

 Kids always get approved later due to the potential impact on development.  Kids get exposed to one protein from the vaccine and to all of them with the virus itself (same as adults).  Delta is going to find nearly everyone in the end, a process that is simply "natural vaccination," which is a tougher way to go for many, including "unlucky" supposedly healthy younger patients.  But of course, discuss with the pediatrician as needed.  ;)